Vertex Pharmaceuticals Incorporated
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| VRTX34.SA | 095700.KQ | CSL.AX | KRYS | ROIV | 1530.HK | |
|---|---|---|---|---|---|---|
| Market cap | 757.54B | 94.14B | 97.13B | 9.21B | 27.61B | 37.99B |
| P/E (TTM) | 36.9 | — | — | 42.2 | — | 4.1 |
| Forward P/E | — | — | 21.5 | 34.0 | -27.5 | 11.2 |
| Price/book | 7.3 | — | 4.6 | 6.4 | 6.5 | 1.2 |
| Dividend yield | — | — | 2.05% | — | — | 1.69% |
| 1-year change | +29.63% | −60.56% | +11.91% | +55.44% | +85.85% | −51.32% |
| Today | +2.01% | +0.73% | +2.56% | +1.90% | +6.08% | +4.00% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 20 min.
Latest news
All VRTX34.SA news ›Vertex Pharmaceuticals Non-GAAP EPS of $4.76 misses by $0.02, revenue of $3.44B beats by $10M
Vertex’s financial guidance is summarized below: $13.15 to $13.25 billion vs consensus of $13.28B $13.1 to $13.2 billion $0.5 billion or greater $40 to $50 million $7.15 to $7.2 billion $6.3 to $6.45 billion $5.65 to $5.75 billion
Vertex Pharmaceuticals’s (NASDAQ:VRTX) Q3 2026 sales top estimates
Biotech company Vertex Pharmaceuticals VRTXreported Q3 2026 results exceeding the market’s revenue expectations, with revenue up 11.8% year on year to $3.44 billion. On the other hand, the company’s full-year revenue guidance of $13.2…
VERTEX PHARMACEUTICALS ($VRTX) Releases Q3 2026 Earnings, Stock Rises
VERTEX PHARMACEUTICALS ($VRTX) posted quarterly earnings results for Q3 2026 on Monday, November 2nd. The company reported earnings of $4.76 per share, missing estimates of $4.88 by $0.12. The company also reported revenue of…
More from 1 other outlet
VRTX News Today | Why did Vertex Pharmaceuticals stock go up today?
VRTX News Today | Why did Vertex Pharmaceuticals stock go down today? $VRTX MarketBeat Vertex Pharmaceuticals (VRTX) News Today Why Is Vertex Pharmaceuticals Down Today? Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) reported mixed…
More from 1 other outlet
Vertex Pharmaceuticals (VRTX) Set to Report Q3 Earnings on November 2
On November 01, 2026, Vertex Pharmaceuticals Inc VRTX is scheduled to release its Q3 earnings after market close. Investors and analysts will be closely watching the company’s performance amid mixed recent estimate revisions and a strong…
Vertex Pharmaceuticals Incorporated $VRTX Stock Sold by Sumitomo Mitsui Trust Group Inc.
Posted by Mitch Edgeman on Nov 1st, 2026 Read Our Latest Stock Report on Vertex Pharmaceuticals Vertex Pharmaceuticals Incorporated is a global biotechnology company focused on developing and commercializing medicines for serious diseases.…
Vertex Pharmaceuticals eyes $500M non-CF revenue milestone as Q3 results approach Nov 2
Vertex Pharmaceuticals will report Q3 results on Nov 2, with focus on whether its non-cystic fibrosis drugs CASGEVY and JOURNAVX meet the $500 million revenue target. Q2 revenue rose 12.4% to $3.33 billion, beating estimates, though…
Analysts Are Bullish on These Healthcare Stocks: Vertex Pharmaceuticals (VRTX), Oxford BioMedica (OXBDF)
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Vertex Pharmaceuticals (VRTX) and Oxford BioMedica (OXBDF) with bullish sentiments. In a report released today, Phil Nadeau from TD Cowen…
Vertex Pharmaceuticals (NASDAQ:VRTX) Beats Q1 CY2026 Sales Expectations
Biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) beat Wall Street’s revenue expectations in Q1 CY2026, with sales up 7.8% year on year to $2.99 billion. The company expects the full year’s revenue to be around $13.03 billion, close to…
Vertex Pharmaceuticals Reaches $558.88, a Fresh 52-Week Peak
As seen on the 24/7 Wall St. homepage on October 30, 2026. Vertex Pharmaceuticals closed at $558.88, a fresh 52-week high and 0.16% above the September 3 peak. The $141.7 billion biotech has now reclaimed the top of its range after a…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Themes
Most coverage from
- marketscreener.com17
- fool.com6
- theglobeandmail.com6
- gurufocus.com4
- themarketsdaily.com4
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 60 articles, not a forecast.